WO2008134445A8 - Platelet activation receptor clec-2: compositions and uses thereof - Google Patents
Platelet activation receptor clec-2: compositions and uses thereof Download PDFInfo
- Publication number
- WO2008134445A8 WO2008134445A8 PCT/US2008/061446 US2008061446W WO2008134445A8 WO 2008134445 A8 WO2008134445 A8 WO 2008134445A8 US 2008061446 W US2008061446 W US 2008061446W WO 2008134445 A8 WO2008134445 A8 WO 2008134445A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- clec
- podoplanin
- compositions
- disclosed
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Disclosed are compositions comprising the platelet activation receptor C-type Lectin- like Receptor 2 (CLEC-2), and compositions comprising anti-CLEC-2 antibodies or antibodies that inhibit the interaction of CLEC-2 with podoplanin. Also disclosed are and methods of treating subjects in need thereof, comprising administering to the subject an effective amount of the disclosed compositions. Disclosed are recombinant CLEC-2 polypeptides, nucleic acids, antibodies, and compositions comprising recombinant CLEC-2 polypeptides, nucleic acids and antibodies. CLEC-2, has been found to interact with podoplanin. Recombinant CLEC-2 inhibits platelet aggregation induced by podoplanin- expressing tumor cells or lymphatic endothelial cells. Thus, CLEC-2 is responsible for platelet aggregation induced by endogenously expressed podoplanin on cell surfaces. CLEC- 2 is therefore a physiological target protein of podoplanin and is involved in podoplanin- induced platelet aggregation, tumor metastasis, and other cellular responses related to podoplanin. Disclosed are methods of treating, for instance, platelet aggregation-related disorders by administering effective amounts of the disclosed compositions to subjects in need thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91390907P | 2007-04-25 | 2007-04-25 | |
US60/913,909 | 2007-04-25 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2008134445A2 WO2008134445A2 (en) | 2008-11-06 |
WO2008134445A3 WO2008134445A3 (en) | 2009-04-30 |
WO2008134445A8 true WO2008134445A8 (en) | 2009-07-30 |
Family
ID=39745183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/061446 WO2008134445A2 (en) | 2007-04-25 | 2008-04-24 | Platelet activation receptor clec-2: compositions and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008134445A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2269597A1 (en) * | 2009-06-22 | 2011-01-05 | CSL Behring GmbH | CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis |
JP2013545443A (en) * | 2010-10-14 | 2013-12-26 | リガド・バイオサイエンシーズ・インコーポレーテツド | CLEC-2 nucleic acid modulator |
CA2838340A1 (en) * | 2011-06-17 | 2012-12-20 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using clec-2 |
EP2895184A4 (en) * | 2012-09-12 | 2016-09-07 | Oklahoma Med Res Found | Modulation of podoplanin mediated platelet activation |
JP6847434B2 (en) * | 2017-03-30 | 2021-03-24 | 国立大学法人東北大学 | Anti-podopranine antibody |
CN108478783B (en) * | 2018-03-30 | 2021-03-23 | 苏州大学 | Application of CLEC-2 in preparation of medicines for treating craniocerebral injury |
-
2008
- 2008-04-24 WO PCT/US2008/061446 patent/WO2008134445A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2008134445A3 (en) | 2009-04-30 |
WO2008134445A2 (en) | 2008-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008134445A8 (en) | Platelet activation receptor clec-2: compositions and uses thereof | |
MX2010011957A (en) | Improved fibronectin-based binding molecules and uses thereof. | |
JOP20190017B1 (en) | Human cgrp receptor binding antibodies | |
WO2014100439A3 (en) | B7-h4 specific antibodies, and compositions and methods of use thereof | |
WO2006033854A3 (en) | Aptamers to von willebrand factor and their use as thrombotic disease therapeutics | |
WO2011140086A3 (en) | Serum albumin binding molecules | |
WO2020077276A3 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
WO2009038760A3 (en) | Human gm-csf antigen binding proteins | |
EP2371390A3 (en) | Antagonists and methods of use therefor | |
EA201170312A1 (en) | SELECTIVE ANTIBODIES TO HEPCIDINE-25 AND THEIR APPLICATION | |
MX2008009886A (en) | Antibodies that bind par-2. | |
WO2004078938A3 (en) | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof | |
WO2006073941A3 (en) | Polypeptides that bind br3 and uses thereof | |
WO2007005786A3 (en) | Methods and compositions with enhanced therapeutic activity | |
EP3670536A3 (en) | Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof | |
WO2011060206A3 (en) | Material and methods for treating or preventing her-3 associated diseases | |
MX2009013824A (en) | Antigen binding proteins that bind par-2. | |
DK2343320T3 (en) | ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF | |
WO2007025049A3 (en) | Aptamers that bind thrombin with high affinity | |
WO2006036922A3 (en) | Srage mimetibody, compositions, methods and uses | |
WO2006020060A3 (en) | Iap binding compounds | |
BR112012031329A2 (en) | vstm3 dimeric fusion proteins and related compositions and methods | |
ATE414725T1 (en) | AMPHOTERELIC ETHYL METHACRYLATE COPOLYMERS AND USE THEREOF | |
MY153751A (en) | Antibodies directed to her-3 and uses thereof | |
EA200801174A1 (en) | GLP-2 MIMETIC ANTIBODIES, POLYPEPTIDES, COMPOSITIONS, METHODS AND APPLICATIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08746806 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08746806 Country of ref document: EP Kind code of ref document: A2 |